A radioimmunoassay for ornithine decarboxylase was used to study the regulation of this enzyme in rat liver. The antiserum used reacts with ornithine decarboxylase from mouse, human or rat cells. Rat liver ornithine decarboxylase enzyme activity and enzyme protein (as determined by radioimmunoassay) were measured in thioacetamide-treated rats at various times after administration of 1,3-diaminopropane. Enzyme activity declined rapidly after 1,3-diaminopropane treatment as did the amount of enzyme protein, although the disappearance of enzyme activity slightly preceded the loss of immunoreactive protein. The loss of enzyme protein after cycloheximide treatment also occurred rapidly, but was significantly slower than that seen with 1,3-diaminopropane. When 1,3-diaminopropane and cycloheximide were injected simultaneously, the rate of disappearance of enzyme activity and enzyme protein was the same as that seen with cycloheximide alone. These results show that the rapid loss in enzyme activity after 1,3-diaminopropane treatment is primarily due to a loss in enzyme protein and that protein synthesis is needed in order for 1,3-diaminopropane to exert its full effect. A macromolecular inhibitor of ornithine decarboxylase that has been termed antizyme is induced in response to 1,3-diaminopropane, but our results indicate that the loss of enzyme activity is not due to
the accumulation of inactive ornithine decarboxylase-antizyme complexes. It is possible that the antizyme enhances the degradation of the enzyme protein. Control experiments demonstrated that the antiserum used would have detected any inactive antizyme-ornithine decarboxylase complexes present in liver since addition of antizyme to ornithine decarboxylase in vitro did not affect the amount of ornithine decarboxylase detected in our radioimmunoassay. Anti-(ornithine decarboxylase) antibodies may be useful in the purification of antizyme since the antizyme-ornithine decarboxylase complex can be immunoprecipitated, and antizyme released from the precipitate with 0.3M-NaCl.
Ornithine decarboxylase catalyses the conversion of ornithine into putrescine (Pegg & WilliamsAshman, 1968 Tabor & Tabor, 1976; McCann, 1980) , which is the sole precursor of the polyamines in mammalian tissues. This enzyme has been of great interest in recent years owing to its rapid and many-fold stimulation by a number of physiological and pharmacological agents (Russell, 1980; Pegg & Williams-Ashman, 1981) .
The apparent half-life of ornithine decarboxylase activity has been reported to be from 15 to 90min, which is shorter than that known for any other mammalian enzyme (Russell & Snyder, 1969; Holtta, 1975; Prouty, 1976; Jefferson & Pegg, 1977; Seely et al., 1982a,b) . The most probable reason for the rapid decline in enzyme activity after the removal of a stimulating agent or inhibition of protein synthesis is that the protein turns over very rapidly and there is direct evidence to support this (Seely et al., 1982a; Seely & Pegg, 1983) . However, a number of other explanations have been forwarded concerning this rapid loss of enzyme activity, including covalent modification via phosphorylation (Atmar & Kuehn, 1981 ; Kuehn & Atmar, 1982) or transglutamination (Russell, 1981) , alteration in the affinity of the enzyme for pyridoxal cofactor (Mitchell et al., 1975 (Mitchell et al., , 1978 (Mitchell et al., , 1981 , complexing with inhibitory (Canella- Vol. 216 kis et al., 1979) or stimulatory proteins (Fujita et al., 1982a,b) . Although there is suggestive evidence for these theories, most of the experiments were done in vitro. It is, therefore, not known to what extent (if any) they contribute to the overall regulation of ornithine decarboxylase in vivo.
Certain diamines, particularly putrescine and 1,3-diaminopropane, have been shown to produce a rapid decrease in ornithine decarboxylase activity and the appearance of a 26000-mol.wt. inhibitory protein termed 'antizyme' (Heller et al., 1976; McCann et al., 1977; P6s6 et al., 1978; Pegg et al., 1978; Canellakis et al., 1979) . Antizyme binds and completely inhibits activity in vitro but the antizyme-ornithine decarboxylase complex can be dissociated with high salt concentrations (Heller et al., 1976; McCann et al., 1977) . It has been suggested that the rapid decrease in enzyme activity seen in liver after 1,3-diaminopropane treatment is brought about by the synthesis of antizyme and the formation of enzymically inactive antizyme-ornithine decarboxylase complexes (Heller et al., 1976; Canellakis et al., 1979) .
Attempts to provide definite proof for this hypothesis using antibodies to quantify the amount of enzyme protein were made by Kallio et al. (1977 Kallio et al. ( , 1979 . However, the results were inconclusive, giving contradictory results when the assay was carried out in different ways and, because of the low titre of the antibodies and the small amount of ornithine decarboxylase present in tissues, the protein could be measured only by immunotitration of the activity (Kallio et al., 1979) . Also, the specificity of the antibodies used is seriously in doubt since more recent workers have purified ornithine decarboxylase to a specific activity 50-100 times greater than that used to raise antibodies in these experiments (Persson, 1981; Seely et al., 1982c; Kameji et al., 1982) . More recently, the homogeneous enzyme from mouse kidney (Seely & Pegg, 1983; Persson, 1982) or rat liver (Kameji et al., 1982) has been used to provide specific antisera of much higher titre and proven monospecificity. We have set up a specific radioimmunoassay for the enzyme using such antibodies and the enzyme labelled by reaction with oc-difluoromethyl [5- 3H]ornithine as the tracer ligand.
This radioimmunoassay was used to determine the effect of 1,3-diaminopropane treatment on the levels ofornithine decarboxylase enzyme protein in thioacetamide-treated rat liver. Our (1983) . Mouse kidney ornithine decarboxylase was purified to homogeneity as described by Seely et al. (1982c) and a specific antiserum to the enzyme was raised in rabbits as described by Seely & Pegg (1983 (Pegg et al., 1978) . 1,3-Diaminopropane was administered to the thioacetamide-treated rats by intraperitoneal injection at a dosage of 1 mmol/kg body wt. and the animals were killed at times indicated. Cycloheximide was administered at a dosage of 5 mg/kg body wt. and the animals were killed at times indicated. Livers were homogenized in 2.5 vol. of 25mM-Tris/HCl, pH 7.5, containing 0.1 mM-EDTA, 2.5 mM-dithiothreitol and 0.02% (w/v) Brij 35 (buffer A) and centrifuged at 1000OOg for 45 min. The supernatants were dialysed overnight against 600vol. of buffer A containing 1mM-dithiothreitol. Ornithine decarboxylase activity and immunoreactivity measurements were done on these extracts.
Radioimmunoassay and enzyme activity measurement of ornithine decarboxylase
The radioimmunoassay for ornithine decarboxylase was done as described previously (Seely & Pegg, 1983) (Seely & Pegg, 1983) . Incubation in the presence of tracer ligand was for 30min. The immune complexes were precipitated with bacterial protein A, washed and counted for radioactivity as reported previously (Seely & Pegg, 1983) . Standard curves were set up as described by Seely & Pegg (1983) , except that various amounts of extract from thioacetamide-treated rat liver were used as standard; 100% binding was that amount of tracer ligand bound by the antibody in the presence of 0.6ml of a liver extract containing essentially no (<0.3ng/ml) ornithine de- carboxylase. This liver extract was obtained from rats that were not treated with thioacetamide, but that received cycloheximide 60min before being killed. This extract was also used to adjust the total amount of protein in the standards to 15-20mg. Ornithine decarboxylase enzyme activity was determined by monitoring the release of 14CO2 from (1-14C)-labelled ornithine (Pegg & WilliamsAshman, 1968) . Protein determinations were done by the method of Bradford (1976) . One unit ofornithine decarboxylase activity is that amount that will decarboxylate 1 nmol of ornithine in 30min. One unit of rat liver ornithine decarboxylase was assumed to be equivalent to 1.43ng of enzyme protein based on the fact that one unit binds 26fmol of a-difluoromethylornithine and that one molecule of oa-difluoromethylornithine is bound per 55000-mol. wt. subunit (Pritchard et al., 1981; Seely et al., 1982b antizyme is defined as that amount that will inhibit one unit of ornithine decarboxylase activity.
Results
The radioimmunoassay procedure described previously (Seely & Pegg, 1983) , using cL-difluoromethyl[5-3H]ornithine-labelled mouse kidney ornithine decarboxylase as tracer ligand, can be used to determine ornithine decarboxylase from rat and human as well as mouse (Fig. 1) . Both rat and human ornithine decarboxylase could be determined with roughly the same sensitivity as the mouse enzyme. This finding agrees with the recent paper of Persson (1982) , who showed that antiserum raised in rabbits to mouse kidney ornithine decarboxylase inhibited both rat and mouse ornithine decarboxylase. The fact that the rat standard curve did not parallel the mouse or human curves may suggest that the antibody is recognizing different antigenic determinants on this enzyme, the significance of which is unclear at this time but the rat and mouse enzymes have been shown to have slightly different physical properties (Seely et al., 1982b,c) . By this method we could measure as low as 1 unit of rat liver ornithine decarboxylase protein, which is equivalent to 1.4ng of enzyme protein. When rats were treated with 1,3-diaminopropane, putrescine or cycloheximide, there was a rapid fall in the activity of ornithine decarboxylase (Figs. 2a-2c ). The loss of activity was more rapid with 1,3-diaminopropane than with putrescine and the former was, therefore, chosen for further experiments. As can be seen in Fig. 2(c) , the rate of loss of ornithine decarboxylase protein in response to 1,3-diaminopropane was similar to the rate of loss of enzyme activity. At 45 min after treatment, however, there was a somewhat greater fraction of protein remaining than of activity, which could indicate the presence of a small amount of antizyme-ornithine decarboxylase complexes. By 4h after treatment, both enzyme activity and enzyme protein had fallen below the limit of detection. Although there may be a small amount of enzymically inactive antizyme-ornithine decarboxylase complex formed at 45min after treatment, it is important to note that the major cause of the rapid loss of enzyme activity is the loss of enzyme protein. It is not known to what extent 1,3-diaminopropane affects ornithine decarboxylase synthesis or degradation; these experiments would suggest that inhibition of synthesis is not its sole effect. The rate of loss of enzyme activity after 1,3-diaminopropane treatment was significantly greater than that seen after inhibition of protein synthesis by cycloheximide (Fig. 2a) . This indicates that 1,3-diaminopropane is having an augmentative effect on the rate of ornithine decarboxylase breakdown. Whether this effect is mediated by antizyme or some other factor remains to be elucidated. However, some rapidly synthesized protein appears to be involved, since when cycloheximide was administered simultaneously with 1,3-diaminopropane or with putrescine the loss of enzyme activity and protein was similar to that seen with cycloheximide alone (Figs. 2a, 2b and 3) . In order to validate these resu sary to show that our antib( antizyme-ornithine decarboxylas do this, we made crude (1000( antizyme preparations from 1,3-e treated rats as described in th4 yme using ornithine amount of enzyme protein as determined by radioum immunoassay. This demonstrated that our radioupernatant) was immunoassay procedure was able to detect any ylase in the presornithine decarboxylase bound to antizyme in 1,3-Lntiserum. Antidiaminopropane-treated rat liver. In addition, we )precipitate with were unable to unmask additional ornithine decarMaterials and boxylase immunoreactivity froni samples in Fig. 3 o incubated with by doing the immunoassay in the presence of 0.3M-in the absence of NaCl, a condition that would dissociate any e measurements.' erials and methantizyme-ornithine decarboxylase complexes that may have been present (results not shown).
Since and immunoassays were performed. The crude antizyme and ornithine decarboxylase were incubated together for 5min at 0-40C before addition of antiserum to start the radioimmunoassay. Incubation for longer times at higher temperature (37°C) before the addition of antibody had no effect on the measurable amount of immunoreactivity. As can be seen in Table 1 , even when antizyme was added in proportions such that only 11% of the ornithine decarboxylase activity remained, there was still no effect on the measurable
Discussion
The effect of 1,3-diaminopropane on ornithine decarboxylase from rat liver is quite striking and undoubtedly complicated. Although 1,3-diaminopropane may cause direct inhibition of protein synthesis at relatively high concentrations (Kay & Benzie, 1980; Tuomi et al., 1980) , the rate of loss of enzyme protein after 1,3-diaminopropane treatment is greater than in animals treated with cycloheximide, indicating that the diamine leads to an increased rate of enzyme degradation. The enhanced rate of enzyme breakdown can be blocked
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by cycloheximide (Fig. 3) (Woodside, 1976) . This is unlikely to explain our results, since direct measurements of the turnover of ornithine decarboxylase protein in mouse kidney indicated that the protein was degraded at the same rate in the presence or absence of cycloheximide (Seely et al., 1982a) .
It is conceivable that our antibody preparations are unable to recognize an altered form of ornithine decarboxylase that is formed in the diaminetreated liver. However, this is highly unlikely since the antibody does interact with the complex between antizyme and ornithine decarboxylase (Table 1) , ornithine decarboxylase conjugated with cx-difluoromethylornithine (Seely & Pegg, 1983) and aggregated forms of the enzyme produced on prolonged storage (J. E. Seely & A. E. Pegg, unpublished work) .
Results from a number of experiments in vitro have suggested that ornithine decarboxylase activity may be regulated by post-translational modifications (Atmar & Kuehn, 1981; Russell, 1981) or by inhibitory or stimulatory proteins (Canellakis et al., 1979; Fujita et al., 1982a,b) . The experiments in vivo reported in the present paper, however, in which both enzyme-activity and enzyme-protein measurements were made, suggest that in liver the net regulation of ornithine decarboxylase activity is primarily at the level of synthesis and degradation de novo. Similar results were obtained when the regulation of ornithine decarboxylase in mouse kidney was tested, but this may be a special case since enzyme levels 100-200 times greater than in other cell types exist in the male mouse kidney (Seely & Pegg, 1983 ). This is not to say that post-translational modification or enzymeinhibitory proteins such as antizyme play no role in ornithine decarboxylase regulation. Rather, such enzyme modifications may be prerequisites in order for ornithine decarboxylase degradation to occur. One could speculate that the role of antizyme is to make ornithine decarboxylase available to a particular fast-acting proteolytic system. Antizyme could then be either degraded or freed to bind another ornithine decarboxylase molecule. This could explain why few (if any) antizyme-ornithine decarboxylase complexes are detected in vivo. Such a mechanism would not be dissimilar from the ATP-ubiquitin proteolytic system from reticulocytes (Etlinger & Goldberg, 1977; Wilkinson et al., 1980) in which proteins are 'earmarked' for degradation by conjunction to the protein ubiquitin. Also, it is conceivable that our results can be explained by a sequestration of ornithine decarboxylase-antizyme complexes into some subcellular organelle since our measurements were made only on the soluble fraction from the homogenates. The purification technique for antizyme herein described may be very useful in elucidating the function of this unique protein.
